Comparative speed of kill of sarolaner (Simparica™) and afoxolaner (NexGard®) against induced infestations of *Ixodes scapularis* on dogs

Robert H. Six 1*, David R. Young 2, Melanie R. Myers 1 and Sean P. Mahabir 1

Abstract

**Background:** The black-legged (or deer) tick, *Ixodes scapularis*, commonly infests dogs and cats in North America and is the main vector for the pathogen that causes Lyme disease in dogs and humans. The speed of kill of a parasiticide is critical to minimize the direct and deleterious effects of tick infestation and especially to reduce the risk of tick-borne pathogen transmission. In this study, speed of kill of a novel orally administered isoxazoline parasiticide, sarolaner chewable tablets (Simparica™), against *I. scapularis* on dogs was evaluated and compared with afoxolaner (NexGard®) for five weeks after a single oral dose.

**Methods:** Twenty four dogs were randomly allocated to treatment with either placebo, sarolaner (2 to 4 mg/kg), or afoxolaner (2.5 to 6.8 mg/kg) based on pretreatment tick counts. Dogs were examined and live ticks counted at 8, 12, and 24 h after treatment and subsequent re-infestations on Days 7, 14, 21, 28 and 35. Efficacy was determined at each time point relative to counts for placebo dogs.

**Results:** A single oral dose of sarolaner provided >99% efficacy within 24 h of treatment and >95% against subsequent weekly re-infestations of ticks consistently to Day 35. For the earlier time points, sarolaner significantly reduced tick counts versus placebo from Day 0 to Day 21 at 8 and 12 h, and on Day 35 at 12 h (P ≤ 0.0174), while afoxolaner was only significantly lower at 8 h on Days 0 and 14 (P ≤ 0.0309), and at 12 h on Day 0 only (P < 0.0001). Significantly more live ticks were recovered from afoxolaner-treated dogs than from sarolaner-treated dogs at 24 h after infestation from Day 14 to Day 35 (P ≤ 0.0278). At 24 h, efficacy (based on geometric mean counts) of afoxolaner declined to less than 80% from Day 21 through the end of the study, while efficacy for sarolaner was >95% for 35 days. There were no adverse reactions to treatments.

**Conclusions:** In this controlled laboratory evaluation, sarolaner had a faster speed of kill against *I. scapularis* than afoxolaner. This was noticeably more pronounced towards the end of the monthly treatment period. The rapid and consistent kill of ticks provided by sarolaner within 24 h after a single oral dose and re-infestation over 35 days suggests this treatment will provide highly effective and reliable control of ticks over the entire treatment interval, and should reduce the risk of tick-borne diseases, including Lyme disease whose agent is vectored by *I. scapularis*.

**Keywords:** *Ixodes scapularis*, Tick, Dog, Sarolaner, Simparica™, Afoxolaner, NexGard®, Isoxazoline, Oral, Speed of kill

* Correspondence: robert.six@zoetis.com
1Zoetis, Veterinary Medicine Research and Development, 333 Portage St., Kalamazoo, MI 49007, USA
© 2016 Six et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source; provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The black-legged (or deer tick), *Ixodes scapularis*, is one of the ticks most commonly infesting dogs and cats in North America [1]. The tick species is widely distributed in the northeastern and upper midwestern United States and southeastern to southcentral Canada. The occurrence and geographic distribution of *I. scapularis* ticks is increasing due to the mobility of people and pets, as well as the increase in wildlife populations in urban environments. The infestation of migratory birds also contributes to the geographic expansion increasing the disease risk for humans, wildlife, and domestic animals [2, 3].

*Ixodes scapularis* ticks have become an increasingly important concern for public and veterinary health [4]. These ticks serve as vectors of *Borrelia burgdorferi* and *Anaplasma phagocytophilum*, the causative agents of Lyme borreliosis and granulocytic anaplasmosis in humans and dogs, and may also transmit *Babesia microti*. [5, 6]. *Ixodes scapularis* can also secrete a salivary neurotoxin, which may cause tick paralysis in dogs and humans [1]. The toxin affects the lower motor neurons of the spinal cord and cranial nerves and produces a progressive, ascending flaccid paralysis [7].

Tick control and prevention have taken on a new importance as awareness of and exposure to tick-borne diseases increases and *I. scapularis* (and other tick species) populations continue to expand. Until recently, topically administered parasiticides with contact activity have been the most common approach to tick control on the dog. A new class of compounds, the isoxazolines, have efficacy against fleas and ticks for 1 month or longer following a single oral dose [8, 9]. These systemically active compounds act rapidly to impact the tick’s feeding behavior and cause death of the ticks. Afoxolaner has been reported to provide >90% efficacy against *Ixodes ricinus* within 24 h for up to 28 days after a single dose [10], and sarolaner has similarly demonstrated >90% efficacy against both *I. scapularis* and *I. ricinus* for 28 days [11]. While tick efficacy claims are generally based on evaluation at 48 h after treatment or re-infestation [12], the speed of acaricidal activity is critical in disrupting or preventing feeding and thus reducing the risk of pathogen transmission which generally occurs after the infected tick is attached and feeding for 24 to 48 h [13, 14].

Sarolaner is a novel isoxazoline which in a chewable tablet formulation (Simparica™) provides excellent control of fleas and ticks for at least one month after a single oral dose (TIL McTier, personal communications). A laboratory study was conducted to evaluate and compare the speed of kill of sarolaner and afoxolaner (Nexgard™) against existing *I. scapularis* infestations and weekly re-infestations for a period of 5 weeks after treatment with a single dose.

Methods
The study was a masked, negative-controlled, randomized laboratory efficacy design conducted in California, USA. Study procedures were in accordance with the World Association for the Advancement of Veterinary Parasitology (WAAVP) guidelines for evaluating the efficacy of parasitcides for the treatment, prevention and control of flea and tick infestation on dogs and cats [12] and complied with the principles of Good Clinical Practices [15]. The protocol was reviewed and approved by the local Institutional Animal Care and Use Committee. Masking of the study was assured through the separation of functions. All personnel conducting observations or animal care or performing infestations and counts were masked to treatment allocation.

Animals
Twenty-four, male and female, purpose-bred Beagles from 1 to 3 years of age and weighing from 8.1 to 13.8 kg were used in the study. Each dog was individually identified by a unique ear tattoo or electronic transponder and had undergone an adequate wash-out period to ensure that no residual ectoparasiticide efficacy remained from any previously administered treatments. Dogs were individually housed in indoor runs such that no physical contact was possible between them and were acclimatized to these conditions for at least 14 days prior to treatment. Dogs were fed an appropriate maintenance ration of a commercial dry canine feed for the duration of the study. Water was available ad libitum. All dogs were given a physical exam to ensure that they were in good health at enrollment and suitable for inclusion in the study. General health observations were performed twice daily throughout the study.

Design
The study followed a randomized complete block design. Dogs were ranked according to decreasing tick counts into blocks of three and within each block a dog was randomly allocated to treatment with placebo, sarolaner, or afoxolaner. There were eight dogs per treatment group. Dogs were infested with ticks two days prior to treatment and then weekly for five weeks. Tick counts were conducted at 8, 12, and 24 h after treatment and each subsequent weekly re-infestation.

Treatment
Bodyweights collected on Day 2 were used to determine the appropriate dose to be administered. On Day 0, dogs received either a placebo tablet, the appropriate strength sarolaner chewable tablet (Simparica™), to provide sarolaner at the recommended dose of 2 mg/kg (range: 2 to 4 mg/kg), or NexGard™ per label directions (afoxolaner at 2.5 to 6.8 mg/kg). All doses were
administered by hand pilling to ensure accurate and complete dosing. Each dog was observed for several minutes after dosing for evidence that the dose was swallowed, and for general health at 1, 4, and 24 h after treatment administration.

**Tick infestation and assessment**

The ticks were obtained from the Oklahoma State University’s *I. scapularis* colony which was initiated in 1991 with engorged females collected locally in Stillwater, OK. The colony has been maintained with the introduction of engorged females collected from the local natural population every two years.

Tick infestations were performed on Days 7 (host suitability and allocation), 2, 7, 14, 21, 28, and 35. Prior to each infestation, the dog was lightly sedated with ketamine/xylazine and a precounted aliquot of 50 (±5) viable unfed adult *I. scapularis* were directly applied to the dog, which was then confined in an appropriately sized travel crate for 4 h to restrict movement and facilitate tick attachment. Each dog was examined to remove and count live ticks at 48 h after the initial host suitability infestation. At 8 and 12 (±0.5) hours after treatment and each subsequent weekly re-infestation, the dogs were examined systematically so that the entire body surface was carefully examined and live ticks were counted *in situ*. At 24 h after treatment and each subsequent weekly re-infestation, the dogs were examined and then thoroughly combed to count and remove live ticks. Each dog was examined for at least 10 min. If ticks were encountered in the last minute, combing was continued in 1 min increments until no ticks were encountered.

**Statistical analysis**

The individual dog was the experimental unit and the primary endpoint was live tick counts. Data for post-treatment live (free plus attached) tick counts were summarized with arithmetic (AM) and geometric (GM) means by treatment group and time point. Tick counts were transformed by the loge(count + 1) transformation prior to analysis in order to stabilize the variance and normalize the data. Using the PROC MIXED procedure (SAS 9.2, Cary NC), transformed counts were analyzed using a mixed linear model. The fixed effects were treatment, timepoint and the interaction between timepoint and treatment by timepoint. The random effects included block, block by treatment interaction, and error. Testing was two-sided at the significance level α = 0.05.

The assessment of efficacy for live ticks was based on the percent reduction in the AM and GM live tick counts relative to placebo and to the positive control, as suggested by the most recent guidelines of the WAAVP for systemic acaricides [11], and was calculated using Abbott’s formula:

\[
\% \text{ reduction} = 100 \times \frac{\text{mean count (placebo)} - \text{mean count (treated)}}{\text{mean count (placebo)}}
\]

**Results**

There were no treatment-related adverse events during the study. Placebo-treated dogs maintained good tick infestations throughout the study with mean tick counts ranging from approximately 20 to 33 (Tables 1, 2 and 3). At the 8-h timepoint, treatment with sarolaner resulted in significantly lower tick counts than placebo-treated dogs (\( P < 0.0174 \)) from treatment through Day 21, and efficacy (GM) ranged from 30.3 to 38.0 % for this period (Table 1). Treatment with afoxolaner resulted in significantly lower tick counts than placebo at 8 h on Days 0 and 14 only (\( P < 0.0309 \)), with efficacy (GM) of 39.6 and 30.8 %, respectively (Table 1). There were no significant differences between the mean live tick counts at 8 h for the sarolaner- and afoxolaner-treated dogs on any day (\( P \geq 0.1028 \)).

At the 12-h timepoint, sarolaner-treated dogs had significantly lower tick counts than placebo-treated dogs (\( P < 0.0131 \)) from treatment through Day 21, and on Day 35, with efficacy (GM) ranging from 53.3 to 74.9 % (Table 2). Treatment with afoxolaner resulted in significantly lower tick counts than placebo at 12 h on Day 0 only (\( P < 0.0001 \)), with efficacy (GM) of 68.1 %. Efficacy for afoxolaner was 31.1 % on all other days (Table 2). Tick counts were significantly higher for afoxolaner-treated dogs than for sarolaner-treated dogs on Days 7 and 21 (\( P < 0.0006 \)).

At the 24-h time point, both treatments resulted in significantly lower tick counts than placebo-treated dogs (\( P < 0.0310 \)) throughout the study, and sarolaner-treated dogs also had significantly fewer ticks than afoxolaner-treated dogs (\( P < 0.0278 \)) on Days 14, 21, 28, and 35 (Table 3). Treatment with sarolaner resulted in efficacy (GM) of at least 95.7 % through Day 35, while efficacy for dogs treated with afoxolaner declined below 80 % from Day 21 onwards (Table 3, Fig. 1).

**Discussion**

A single dose of sarolaner resulted in the rapid reduction of an existing infestation with *I. scapularis* ticks and the rapid kill of re-infestations for 5 weeks after treatment. Efficacy of >90 % was achieved within 24 h for 28 days. Rapid kill of ticks is key to ameliorating the direct adverse effects of tick feeding and is critical in reducing the risk of transmission of tick-borne pathogens. Transmission of *B. burgdorferi* is considered not to occur until ticks are attached for at least 48 h [16, 17], and transmission rates of *B. burgdorferi* and *A. phagocytophilum* have been shown to drop significantly if ticks are...
Table 1 Mean live *Ixodes scapularis* counts and efficacy relative to placebo at 8 h after treatment and post-treatment re-infestations for dogs treated with a single oral dose of sarolaner or afoxolaner on Day 0

| Treatment | Day of treatment or re-infestation | 0  | 7  | 14 | 21 | 28 | 35 |
|-----------|-----------------------------------|----|----|----|----|----|----|
| Placebo   | Range                             | 20–40 | 12–32 | 17–37 | 18–40 | 12–32 | 15–34 |
|           | A. mean                           | 30.3 | 25.5 | 25.4 | 28.6 | 24.1 | 23.8 |
|           | G. mean¹                          | 29.4ᵃ | 24.2ᵃ | 24.5ᵃ | 27.8ᵃ | 23.2ᵃ | 23.0ᵃ |
| Sarolaner | Range                             | 15–25 | 11–24 | 10–30 | 13–36 | 16–35 | 13–36 |
|           | A. mean                           | 20.8 | 16.8 | 16.1 | 19.6 | 25.6 | 23.1 |
|           | Efficacy (%)                       | 31.4 | 34.3 | 36.5 | 31.4 | 0.0  | 2.6  |
|           | G. mean¹                          | 20.5ᵇ | 16.2ᵇ | 15.2ᵇ | 18.5ᵇ | 25.0ᵃ | 21.9ᵃ |
|           | Efficacy (%)                       | 30.3 | 32.8 | 38.0 | 33.5 | 0.0  | 5.0  |
|           | P-value vs. placebo               | 0.0082 | 0.0174 | 0.0070 | 0.0065 | 0.5822 | 0.6940 |
|           | P-value vs. sarolaner             | 0.2569 | 0.1028 | 0.5023 | 0.1487 | 0.4914 | 0.4585 |

¹Geometric means within columns with the same superscript are not significantly different (P > 0.05)

Table 2 Mean live *Ixodes scapularis* counts and efficacy relative to placebo at 12 h after treatment and post-treatment re-infestations for dogs treated with a single oral dose of sarolaner or afoxolaner on Day 0

| Treatment | Day of treatment or re-infestation | 0  | 7  | 14 | 21 | 28 | 35 |
|-----------|-----------------------------------|----|----|----|----|----|----|
| Placebo   | Range                             | 20–43 | 13–30 | 10–39 | 15–36 | 15–36 | 18–33 |
|           | A. mean                           | 32.9 | 23.1 | 24.4 | 26.3 | 23.9 | 25.4 |
|           | G. mean¹                          | 32.0ᵃ | 22.3ᵃ | 22.6ᵃ | 25.4ᵃ | 23.1ᵃ | 24.7ᵃ |
| Sarolaner | Range                             | 4–22 | 6–14 | 0–18 | 1–26 | 12–35 | 1–29 |
|           | A. mean                           | 9.1  | 9.5  | 12.1 | 10.3 | 18.6 | 15.4 |
|           | Efficacy (%)                       | 72.2 | 58.9 | 50.3 | 61.0 | 22.0 | 39.4 |
|           | G. mean¹                          | 8.0ᵇ | 9.1ᵇ | 9.5ᵇ | 7.9ᵇ | 17.5ᵇ | 11.6ᵇ |
|           | Efficacy (%)                       | 74.9 | 59.2 | 58.0 | 68.8 | 24.0 | 53.3 |
|           | P-value vs. placebo               | <0.0001 | <0.0001 | 0.0120 | 0.0002 | 0.1054 | 0.0131 |
|           | P-value vs. sarolaner             | 0.3063 | 0.0004 | 0.1369 | 0.0006 | 0.4123 | 0.0949 |

¹Geometric means within columns with the same superscript are not significantly different (P > 0.05)
Prevented from feeding for more than 24 h [18]. Thus, the rapid efficacy of a single oral dose of sarolaner demonstrated here that resulted in the kill of the majority of ticks within 24 h of weekly re-infestations for 1 month should provide a marked reduction in the risk of a treated dog becoming infected with the pathogens transmitted by *I. scapularis*.

Efficacy of afoxolaner against *I. scapularis* has been described previously with assessment at 48 h after treatment and weekly re-infestations; Mitchell et al. [19]

**Table 3** Mean live *Ixodes scapularis* counts and efficacy relative to placebo at 24 h after treatment and post-treatment re-infestations for dogs treated with a single oral dose of sarolaner or afoxolaner on Day 0

| Treatment   | Day of treatment or re-infestation | 0  | 7  | 14 | 21 | 28 | 35 |
|-------------|-----------------------------------|----|----|----|----|----|----|
| Placebo     | Range                             | 26–39 | 3–32 | 12–32 | 4–36 | 16–32 | 14–29 |
|             | A. mean                           | 32.4 | 23.9 | 23.4 | 27.5 | 23.5 | 22.9 |
|             | G. mean                           | 32.0<sup>a</sup> | 20.5<sup>a</sup> | 22.4<sup>a</sup> | 23.9<sup>a</sup> | 23.1<sup>a</sup> | 22.4<sup>a</sup> |
| Sarolaner   | Range                             | 0–1 | 0–1 | 0–0 | 0–3 | 0–5 | 0–17 |
|             | A. mean                           | 0.1 | 0.3 | 0.0 | 0.5 | 1.3 | 2.6 |
|             | Efficacy (%)                       | 99.6 | 99.0 | 100 | 98.2 | 94.7 | 88.5 |
|             | G. mean                           | 0.1<sup>b</sup> | 0.2<sup>b</sup> | 0.0<sup>c</sup> | 0.3<sup>c</sup> | 0.8<sup>c</sup> | 1.0<sup>c</sup> |
|             | Efficacy (%)                       | 99.7 | 99.1 | 100 | 98.8 | 96.8 | 95.7 |
|             | P-value vs. placebo                | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
| Afoxolaner  | Range                             | 0–2 | 0–6 | 0–9 | 1–15 | 1–21 | 0–25 |
|             | A. mean                           | 0.3 | 1.8 | 2.4 | 6.9 | 9.0 | 12.1 |
|             | Efficacy (%)                       | 99.2 | 92.7 | 89.8 | 75.0 | 61.7 | 47.0 |
|             | G. mean                           | 0.1<sup>b</sup> | 1.0<sup>b</sup> | 1.1<sup>b</sup> | 5.3<sup>b</sup> | 6.5<sup>b</sup> | 6.8<sup>b</sup> |
|             | Efficacy (%)                       | 99.5 | 95.1 | 95.1 | 77.9 | 71.8 | 69.6 |
|             | P-value vs. placebo                | <0.0001 | <0.0001 | <0.0001 | 0.0003 | 0.0009 | 0.0310 |
|             | P-value vs. sarolaner              | 0.7558 | 0.1197 | 0.0278 | <0.0001 | 0.0001 | 0.0083 |

<sup>a</sup> Geometric means within columns with the same superscript are not significantly different (*P* > 0.05)

**Fig. 1** Percent efficacy based on geometric mean counts relative to placebo at 12 and 24 h after treatment and weekly post-treatment re-infestations of *Ixodes scapularis* for dogs treated with a single oral dose of sarolaner or afoxolaner on Day 0
reported efficacy (GM) of 98.4 % against an existing infestation and ≥94.2 % against re-infestations up to Day 28. This level of efficacy for afoxolane at 48 h is similar to the efficacy achieved by sarolaner at 24 h in this study, and further highlights the speed of tick kill following a single dose of sarolaner. Also notable was the consistency of sarolaner’s efficacy at 24 h after re-infestations over the duration of the treatment interval, while efficacy of afoxolane at 24 h declined significantly to less than 80 % from Day 21 onwards. This consistent and rapid kill of ticks within 24 h over a full month following a single administration of sarolaner supports the potential for the product to aid in the prevention of the transmission of tick-borne pathogens to dogs.

Conclusions
This study confirmed the excellent acaricidal efficacy of sarolaner against I. scapularis after a single oral administration. Ticks were killed rapidly, with the majority of ticks killed within 24 h after weekly re-infestations for 5 weeks. Efficacy for sarolaner-treated dogs was consistently higher than that of afoxolane from Day 14 onwards at 24 h. Thus, sarolaner chewable tablets (Simparica™) offers the pet owner and the veterinarian an efficacious oral product with a rapid speed of kill of ticks over the entire month following a single oral dose, and will be an important new tool in the treatment and prevention of tick infestation, and should reduce the risk of tick–borne pathogen transmission.

Competing interests
This study was funded by Zoetis, Florham Park, NJ. R.H.S., M.R.M., and S.P.M. are current employees of Zoetis. D.Y. was an independent investigator contracted for this study.

Authors’ contributions
All authors assisted with the design and conduct of the study, interpretation of the data, and manuscript review. All authors read and approved the final manuscript.

Acknowledgements
The authors would like to thank Douglas Rugg for his assistance in preparing this manuscript.

Author details
1Zoetis, Veterinary Medicine Research and Development, 333 Portage St., Kalamazoo, MI 49007, USA. 2WRS, 7243 East Ave, Turlock, CA 95380, USA.

Received: 10 December 2015 Accepted: 14 January 2016

References
1. Blagburn BL, Dryden MW. Biology, treatment and control of flea and tick infestations. Vet Clin Small Anim. 2009;59:1173–200.
2. Hamer SA, Goldberg TL, Kitoru UC, Braen JO, Anderson TK, Loss SR, et al. Wild birds and urban ecology of ticks and tick-borne pathogens, Chicago, Illinois, USA, 2005–2010. Emerg Infect Dis. 2012;18:1589–95.
3. Ogden NH, Lindsay LR, Hanincova K, Barker IR, Bigras-Pouli M, Charron DF, et al. Role of migratory birds in introduction and range expansion of Ixodes scapularis ticks and of Borrelia burgdorferi and Anaplasma phagocytophilum in Canada. Appl Environ Microbiol. 2008;74:1780–90.
4. Dantas-Torres F, Chomel BB, Otranto D. Ticks and tick-borne diseases: a One Health perspective. Trends Parasitol. 2012;28:437–46.
5. Varde S, Beckley J, Schwartz I. Prevalence of tick-borne pathogens in Ixodes scapularis in a rural NJ County. Emerg Infect Dis. 1998;49–7.
6. McCall JW, Baker CF, Mather TN, Chester ST, McCall SD, Irwin JP, et al. The ability of a topical novel combination of fipronil, amitraz and (S)-methoprene to protect dogs from Borrelia burgdorferi and Anaplasma phagocytophilum infections transmitted by Ixodes scapularis. Vet Parasitol. 2011;179:335–42.
7. Scott DW, Miller WH, Griffin CE, Muller and Kirk’s Small Animal Dermatology. Philadelphia: Saunders; 2001. p. 443–5.
8. Rohlich N, Roepeke RT, Zschiesche FE. A randomized, blinded, controlled and multi-centered field study comparing the efficacy and safety of Bravecto® (fluralaner) against Frontline® (fipronil) in flea- and tick-infested dogs. Parasit Vectors. 2014;7:93.
9. Shoop WL, Harline EJ, Gould BR, Waddell ME, McDowell RG, Kinney JB, et al. Discovery and mode of action of afoxolane, a new isoxazoline parasiticide for dogs. Vet Parasitol. 2014;201:79–89.
10. Halos L, Lébon W, Chalvet-Monfrey K, Larsen D, Beugnet F. Immediate efficacy and persistent speed of kill of a novel oral formulation of afoxolane (NexGard™) against induced infestations with Ixodes ricinus ticks. Parasit Vectors. 2014;7:452.
11. Six RH, Everett WR, Young DR, Carter L, Mahabir SP, Honsberger NA, et al. Efficacy of a novel oral formulation of sarolaner (Simparica™) against five common tick species infesting dogs in the United States. VetParasitol. http://dx.doi.org/10.1016/j.vetpar.2015.12.023.
12. Marchiondo AA, Holdsworth PA, Faurie LJ, Rugg D, Hellmann K, Snyder DE, et al. World Association for the Advancement of Veterinary Parasitology (W. A.A.V.P.) 2nd. ed: Guidelines for evaluating the efficacy of parasiticides for the treatment, prevention and control of flea and ticks infestations on dogs and cats. Vet Parasitol. 2013;194:84–97.
13. Little SE. Changing paradigms in understanding transmission of canine tick-borne diseases: the role of interrupted feeding and intrastadial transmission. In: 2nd Canine Vector-Borne Disease (CVBD) Symposium. Mezara del Vallo, Sicily, Italy, 2007. p. 30–4. http://www.cvbd.org/fileadmin/media/cvbd/Proceedings_CVBD_2007_FINAL23042007.pdf.
14. Salinas LJ, Greenfield RA, Little SE, Voskuhl GW. Tick-borne infections in the southern United States. Am J Med Sci. 2010;340:194–201.
15. EMEA. Guideline on good clinical practices. VICH Topic GL9. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/ WC500004343.pdf. Accessed 23 Aug 2015.
16. Kidd L, Breitschwerdt EB. Transmission times and prevention of tick-borne diseases in dogs. Compend Contin Educ Pract Vet. 2003;10:742–51.
17. Crippa M, Rais Q, Germ L. Investigations on the mode and dynamics of transmission and infectivity of Borrelia burgdorferi sensu stricto and Borrelia afzelii in Ixodes ricinus ticks. Vector Borne Zoonotic Dis. 2002;2:3–9.
18. Prulfage JB, Hair JA, Everett WR, Yoon SS, Cramer LG, Franke S, et al. The prevention of attachment and the detachment effects of a novel combination of fipronil, amitraz and (S)-methoprene for Rhipicephalus sanguineus and Dermacentor variabilis on dogs. Vet Parasitol. 2011;179:311–7.
19. Mitchell EB, McCall J, Chester ST, Larsen D. Efficacy of afoxolane against Ixodes scapularis ticks in dogs. Vet Parasitol. 2014;201:223–5.

Submit your next manuscript to BioMed Central and we will help you at every step:
• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit